XHKG1875
Market cap159mUSD
Dec 20, Last price
1.60HKD
1D
-1.23%
1Q
-20.00%
IPO
-74.11%
Name
TOT BIOPHARM International Co Ltd
Chart & Performance
Profile
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | |||||||
Revenues | 780,629 76.54% | 442,178 479.34% | 76,325 239.36% | ||||
Cost of revenue | 819,862 | 489,272 | 342,735 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (39,233) | (47,094) | (266,410) | ||||
NOPBT Margin | |||||||
Operating Taxes | 1,000 | (2,599) | 2,461 | ||||
Tax Rate | |||||||
NOPAT | (39,234) | (44,495) | (268,871) | ||||
Net income | (37,757) -24.36% | (49,916) -80.89% | (261,216) -9.46% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 405,788 | 1,990 | |||||
BB yield | -26.45% | ||||||
Debt | |||||||
Debt current | 42,772 | 77,051 | 147,654 | ||||
Long-term debt | 304,245 | 214,374 | 63,510 | ||||
Deferred revenue | 11,000 | ||||||
Other long-term liabilities | 54,050 | 58,767 | 53,453 | ||||
Net debt | (11,347) | (129,525) | 56,876 | ||||
Cash flow | |||||||
Cash from operating activities | 56,431 | 59,929 | (175,137) | ||||
CAPEX | (197,281) | (240,123) | (115,313) | ||||
Cash from investing activities | (164,105) | (282,764) | (108,393) | ||||
Cash from financing activities | 38,225 | 481,240 | 212,082 | ||||
FCF | (186,484) | (221,522) | (356,908) | ||||
Balance | |||||||
Cash | 358,364 | 458,047 | 152,805 | ||||
Long term investments | (37,097) | 1,483 | |||||
Excess cash | 319,333 | 398,841 | 150,472 | ||||
Stockholders' equity | 614,214 | 715,439 | 335,091 | ||||
Invested Capital | 767,054 | 673,357 | 446,637 | ||||
ROIC | |||||||
ROCE | |||||||
EV | |||||||
Common stock shares outstanding | 725,197 | 639,307 | 573,360 | ||||
Price | 1.97 -17.92% | 2.40 | |||||
Market cap | 1,428,638 -6.89% | 1,534,337 | |||||
EV | 1,417,291 | 1,406,369 | |||||
EBITDA | 3,795 | (9,055) | (232,173) | ||||
EV/EBITDA | 373.46 | ||||||
Interest | 5,175 | 6,602 | 2,468 | ||||
Interest/NOPBT |